Connect with us

Cannabis News

What is the Difference Between THC and TAC on Weed Labels?



what is tac compared to thc on weed labels

Over the past few years, the cannabis market in the United States has skyrocketed. You may now choose from hundreds of marijuana products because marijuana is now legal in many jurisdictions and because demand is growing. Each time you visit a dispensary, edibles, THC, and CBD Concentrates, pills, and ointments are all around you. Knowing how to read product labels and comprehend THC levels will help you feel more at ease.


Have you ever experienced information overload when reading cannabis labels such as THC vs.TAC? After all, there are numerous abbreviations, percentages, and ingesting techniques to learn about, and initially, it may seem difficult to choose the proper product. However, if you brush up on your basic cannabis knowledge, you’ll understand everything the label on your product implies.


The TAC number may be the most significant element on a cannabis label, even if THC and CBD are the two cannabinoids that are maybe best known. What does TAC stand for specifically, and why is it important? Does TAC make you higher, too?




Total Active Cannabinoids, or TAC, is the term used to describe the number of active cannabinoids found in cannabis when it was analyzed in a laboratory. Cannabis contains a range of active compounds, in contrast to medicines, which frequently only have one active ingredient.


Over 400 chemicals, including more than 100 cannabinoids, are thought to be present in marijuana (hemp and cannabis). They can generally be divided into the following categories: Cannabinoids, Terpenoids, Flavonoids, Alkaloids, and Glycoproteins.


TAC, an indicator of the quantity of all cannabinoids that make up a cannabis product, is used to gauge its potency. Consider the following important cannabinoids:


Tetrahydrocannabinol (THC)

THC, often known as tetrahydrocannabinol, is the primary ingredient in marijuana. In its active condition, it is known scientifically as delta-9-tetrahydrocannabinol or delta-9-THC. Additionally, this results in the ecstasy or “high” related to marijuana use. It is generally accepted that a high created by high levels of THC will be stronger than one produced by low levels of the active component.


Cannabidiol (CBD)

In addition to THC, CBD is probably the cannabinoid that has the greatest popularity and demand. CBD may provide a number of health advantages, including the reduction of stress and inflammation. All CBD in your product is included in the TAC. Most significantly, unlike THC, CBD does not cause intoxication.


Cannabinol (CBN)

Commonly referred to as the “sleep” cannabinoid is the CBN. CBN is a non-intoxicating substance with a wide spectrum of medicinal effects. Early studies suggest that cannabinol may improve sleep and lessen pain.


Cannabigerol (CBG)

Similar to how CBD might lessen THC’s euphoric effects, CBG has no intoxicating properties. Cannabis users can do this to take advantage of THC’s advantages without experiencing strong highs.


This actiothe endocannabinoid system may mediate this effectmay also be brought on by CBG’s effects on alpha-2 adrenergic receptors, which reduce the activity of the sympathetic nervous system.


Cannabichromene (CBC)

Although this substance has been known for 50 years, its benefits are still unknown. The fact that CBC comes from cannabigerolic acids  (CBGA), like THC and CBD, is recognized. However, how the less popular cannabinoids impact human biology is not well understood.


Inexperienced professionals frequently mispronounce TAC as Total Aerobic Count. The difference between it and Total Active Cannabinoids is that it alludes to a distinct element of the plant’s makeup. You can determine the number of microorganisms in the cannabis sample by calculating the total aerobic count.




As suggested by its name, TAC describes the chemical makeup of any cannabis or hemp plant by supplying a list of the cannabinoids that are active in the plant. The product’s total cannabis content is therefore represented by TAC. TAC considers the full range of active cannabinoids present in the product, which is quite different from THC, which is merely one cannabinoid.




Between TAC and THC components, there is a substantial interaction. For instance, CBD may lessen anxiety brought on by THC, so changing the psychoactive effect as a whole.


Additionally, it is important to remember that some TAC cannabinoids, such as CBGA, aid in the synthesis of THC. Acidic CBGA, a kind of CBG, disintegrates into CBG and then disintegrates even more into other cannabinoids, like THC.




The synergistic interplay of terpenes, cannabinoids, and flavonoids in cannabis is theoretically referred to as the entourage effect. Phytocannabinoids and terpenes, among other elements of the cannabis plant, are said to boost the effects of one another.


Regarding the entourage effect, the TAC is crucial. Nevertheless, fatty acids, flavonoids, and terpenes are additional significant chemicals that exist in addition to cannabinoids. Furthermore, the entourage effect depends on all of the other compounds, even if the bulk of them are insufficiently understood.


Terpenes, which are found in cannabis, give each strain its own distinct flavor. Terpenes are produced by all plants, fruits, and flowers, not just cannabis crops; they are a natural component of all plant life. The terpenes limonene, linalool, pinene, and eucalyptol are some of the more popular ones. Terpenes may also have psychotropic effects, which explains why some terpenes have sedative properties.


But plant pigments come from flavonoids, which are notable for being powerful antioxidants. Along with this, it is still necessary to investigate the process by which they add to the entourage effect.




TAC and THC are being contrasted in order to see which is more advantageous or “greater” in terms of potency or purity. Instead, it indicates that you should definitely consider the percentage of TAC in addition to the THC when choosing a cannabis product, whether it is intended for medical usage or for recreational usage, so as to make a knowledgeable choice. A more thorough picture of the full cannabis product is provided by the TAC percentage. But if strength is your first priority, you might want to opt for a product with a higher THC content. Of course, it is crucial to keep in mind that every individual responds to cannabis differently, so start with a modest dose and gradually raise it as necessary.





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis News

Can Psychedelics Cure or Treat Fibromyalgia?




The probability of treating fibromyalgia with psychedelics in the nearest future has significantly increased following Silo Pharma Inc’s latest announcement about its novel psychedelic compound, which is still in its developmental stage. The reputable pharmaceutical company has begun dosing its newest formulation of Ketamine SP-26, which will be used topically to cure or manage fibromyalgia.


The research team at Silo, the fast-rising developmental-stage psychedelics biotech company, also specified that they would use an IND-enabling study of proprietary time releases while administering the compound during this safety trial.

Overview of Fibromyalgia

Fibromyalgia is one of many disease conditions that affect the nervous system and result in chronic pain or fatigue. Patients who have Fibromyalgia often experience widespread tenderness and ranging levels of pain in their muscles, joints, and other areas of their bodies. Medical researchers and practitioners have explained that Fibromyalgia is not an autoimmune disease; however, they are yet to understand the underlying cause of the complex condition fully.


Fibromyalgia is often confused with Multiple Sclerosis because they possess similar symptoms like muscle weaknesses; however, they are different disease conditions. For instance, Fibromyalgia pain could range from a dull ache to a cascading pain and can be accompanied by tender muscle or tendon spots. Other unique symptoms include restless leg syndrome, chronic fatigue, and fibro fog, otherwise known as a sense of confusion. Before a patient can be officially diagnosed with fibromyalgia, they must have exhibited most of these symptoms for at least three months.


At the time of writing, Fibromyalgia remains a long-term condition with no cure but can be managed with specific medications. These medications help to reduce the patient’s symptoms and improve their general quality of life. According to the American College of Rheumatology, the best methods for managing Fibromyalgia include medical therapy, physical exercises, mental health support, and enough sleep. The latest lift of restrictions on psychedelics has more or less positioned psychedelic compounds as an alternative way to treat Fibromyalgia. And Silo has taken up this challenge.

Silo’s Latest Efforts

In their recent publication, Silo disclosed that the proposed safety evaluation trial to test the suitability of its just-developed novel psychedelic compound would be carried out by a renowned frontage company known as Experimur. The trial will assess the tolerability of SP-26 to determine the right amount of dose that can be administered to a patient. The trial will establish the minimum and maximum dose for a Fibromyalgia patient.


Seeing as the chronic medical condition also causes sleep difficulties, memory loss, and widespread musculoskeletal pain, the team seeks to determine the standard dose administration that can reduce the symptoms and improve the patient’s quality of life.


Eric Weisblum, CEO of Silo Pharmaceuticals Inc, stated in an interview that the company is more than excited to cross this milestone. He acknowledged their partner, Zulo therapeutics, a South Carolina pharma, for working successfully with them till this point. He further spoke of how both companies have successfully developed a new method to efficiently deliver the psychedelic formulation, ketamine, via a time-released sequence. He noted that the novel drug showed a superior ability to reduce neuropathic nerve pains during the project’s pre-clinical studies.


According to Eric, this IND-backed study will help bring the research team closer to testing the novel formulation in real-life fibromyalgia patients.


It is worth noting that Silo Pharma and its regulatory partner are moving forward with their plans to register a pre-investigational New Drug (IND) package submission  SP-26 to the FDA via the 505(b)(2) regulatory pathway. This request specified one or more clinical or nonclinical studies that are required for approval but have not yet been completed by the applicant and for which the applicant lacks the right of reference.

Psychedelics: The Future of Fibromyalgia therapy?

The market for fibromyalgia therapies was estimated by Fortune Business Insights to be worth $764 million in 2020 and $1.4 billion in 2027, with a Compound Annual Growth Rate (CAGR) of 9.2% within the next five years. This shows a massive market for psychedelic producers to fill and profit from while improving thousands of lives.


To some patients, using psychedelics for fibromyalgia may seem weird, but with the development from Silo researchers and others, it’s becoming more apparent that these compounds may help. The FDA may soon allow psychedelic medications like psilocybin and NMDA, according to several researchers.


The Chronic Pain & Fatigue Research Center at the University of Michigan, which has unparalleled experience evaluating treatments for fibromyalgia and other chronic pain indications, explained that nothing is more important to their team than developing psychedelic and psilocybin therapies that will address the daily distress of patients.


In a similar trial to the Silo team’s proposed research, the research center evaluated the safety and efficacy of Tryp’s TRYP-8802 oral formulation of synthetic psilocybin. The treatment also included psychotherapy to address pain through neuroplasticity, which alters and reorganizes neural networks in the brain. At the time, Tryp President and Chief Science Officer Jim Gilligan told the media that he was thrilled to work with other forward-thinking doctors and scientists to provide alternative treatments for common painful conditions like fibromyalgia and multiple sclerosis.


Last year, another pharmaceutical company, Mind Medicine (MindMed), announced plans to study LSD as a treatment for cluster headaches and an unidentified “common, sometimes devastating, chronic pain condition.”

For companies like Silo and Tryp, their objective is to develop psilocybin-based medications to meet unmet medical demands for the treatment of diverse diseases like chronic pain/fatigue and eating problems.

Bottom Line

Fibromyalgia leaves people with extensive physical pain, tiredness, sleepless nights, anxiety, and despair. With upcoming clinical and safety trials, it might be safe to say that psychedelic compounds like SP-26 will join the two most popular treatments for fibromyalgia, non-steroidal anti-inflammatory drugs (NSAIDs) and gabapentinoids (Lyrica, Neurontin), to provide relief for patients. On the plus side, patients will be able to survive without enduring the unpleasant side effects of conventional drugs.


Meanwhile, the use of psychedelics to treat medical conditions, particularly mental health conditions, including anxiety, depression, and other mental health issues, has gained popularity in recent years. In years, LSD, psilocybin, and other psychedelics may also be helpful for pain relief in modest doses.





Source link

Continue Reading

Cannabis News

What Would You Do With $750 Million of Weed?




A thick odour of cannabis pervades many New York suburbs, the outcome of cannabis decriminalization in 2019 – yet cannabis farmers in the state are at a stall as regards getting their products to market.


The state began issuing growing permits to over 200 farms last spring. Growers have since sown seeds, cultivated rows of plants throughout summer, and concluded harvesting just a few weeks ago. Hundreds of thousands of pounds of marijuana, worth millions of dollars, is now ready to be sold at dispensaries.


The only problem is that instead of being sent to major retailers, the cannabis is simply stacking up. Despite a thriving grey market and the state regulator’s repeated guarantees that cannabis outlets will be commonplace by the end of this year, no legal recreational dispensary has been launched in New York.


The stockpiles, estimated to weigh over 300,000 pounds by the Office of Cannabis Management, pose a slew of issues for farmers. To say the least, cannabis can deteriorate with time. According to Cannabis Benchmarks, a research company that tracks wholesale marijuana pricing statewide, the stash may be worth up to $750 million based on an average projected wholesale value of around $2,500 per pound.


Farmers’ near-billion-dollar revenue will decrease if their harvest is distributed slowly. Meanwhile, producers must figure out how to store it permanently, ensuring that the weed remains as fresh as possible while protecting it from pilfering or contamination.


The Office of Cannabis Management Attempts Towards Launching Legal Recreational Dispensaries

Candidates for one of the first 150 individual retail permits and 25 nonprofit permits expect to hear from the state within the next few days, but this positive step by the OCM is merely the beginning of the lengthy process of operating a legal recreational dispensary.


Melany Dobson, CEO of Hudson Cannabis, a 520-acre plantation approximately two hours north of New York City, said: “It’s an unknown path to market.” She says, “We’ve been repeatedly promised that dispensaries will launch before the year runs out.” I’ve acted as if that’s our only form of proof, so we’re ready for it.


Since 2016, Dobson has been leading the business, previously branded Hudson Hemp, with her brother Ben Dobson and sister Freya Dobson. The fields were stark on a bright November day, with wisps of decaying foliage scattered about. Harvest had finished the previous week, and the cannabis was safely stored elsewhere.


The OCM, which monitors cannabis licenses from its headquarters in Albany, has established a high standard for its initial batch of retail operators — and a mountain of paperwork to contend with in the process. The state has guaranteed that the first licenses will go to applicants convicted of marijuana-related charges before the legalization of recreational marijuana, or their relations, as long as they have experience owning and operating a business in New York. A lot of proof is necessary to establish such credentials and a quasi $2,000 application fee.


After a petition complained of unnecessarily stringent regulations, a federal judge in Albany momentarily barred the OCM from awarding retail licenses in several regions, including Brooklyn, last Thursday. “The goal is to have dispensaries operational before the end of the year,” said Aaron Ghitelman, an OCM spokeswoman. “We’re still shooting for the first sales” by 2023.


When it issued cultivation licenses, the regulator prioritized smaller companies that had already been cultivating hemp — typically used in legal CBD products — over large corporations with no history in the state. The licences came with many restrictions, including the requirement that farms grow no more than one acre of the so-called canopy (equal to around two acres of land size) and that most of the cultivation be done outside.


As a result of the typical Northeast environment, New York’s cannabis farmers are forced to work on a tight timetable. Farmers typically plant marijuana seeds in May to enable outdoor growth rather than greenhouse cultivation. The busy season lasts until late October when harvest begins. The challenge for the remainder of 2022 — or however long it takes for legal recreational dispensaries to launch — is keeping the weed green.


Keeping Harvest Green Till Recreational Dispensaries are Launched


Cannabis, like wine, must be stored in a humidity and temperature-controlled condition. For example, the plants must be kept at a specific temperature throughout the drying process. Over time, producers are more concerned about changes in the crop’s potency and odour, though there are also physical changes.


“Old cannabis develops a brownish tint,” Melany explained. When exposed to air, light, and rising temperatures for an extended time, THC degrades into cannabinol, a weaker and ultimately less helpful molecule.


Hudson Cannabis claims to have the capacity to preserve cultivated cannabis in circumstances that restrict degradation for up to 12 months – a costly setup that not every producer can afford. Dozens of stacked yellow and black bins, each holding around five pounds of the plant, already border the company’s storage facility. Nonetheless, the farmers are modifying their operations to account for the delays.


However, not every cannabis farm is similar to Hudson Cannabis, which has substantial funds and a combined decade of experience between Ben Dobson, Hudson Cannabis’ co-founders and Melany. In addition, the company leases large expanses of land to local farmers to pasture grass-fed goats and beef. The Dobsons are confident they will weather the rough patch between harvest and the eventual ground-breaking for retail dispensaries.


The risks are bigger for many other cannabis farms within New York state. In recent years, a surplus of hemp-derived CBD products has resulted in a nationwide drop in wholesale pricing, leaving some farms in financial distress or bankruptcy. Legal THC sales appeared to be a potential solution for such farms to compensate for their losses. According to an August statement from the mayor’s office, the market for recreational cannabis is expected to exceed $1.3 billion in revenue in New York City alone by next year.



Farmers like the Dobsons will remain in a dilemma until legal recreational dispensaries are open. Because cross-state sales are prohibited, growers cannot sell their harvests to outlets in Massachusetts, New Jersey, or other states where retail operations are already in place. It’s either New York or nothing.





Source link

Continue Reading

Cannabis News

Cannabis and International Trade CLE: Join us December 1st!




Register here!

We are excited to announce that Harris Bricken lawyers Adams Lee, Fred Rocafort and Vince Sliwoski will present on Cannabis and International Trade on Thursday, December 1 from 12pm to 1pm EST. This presentation is hosted by the National Customs Brokers & Forwarders Association of America (NCBFAA) by and through the NCBFAA Educational Institute (NEI).

Below is summary description of the panel put together by NEI:

Join our panel of experts in cannabis and international trade law to discuss topics on the current and future status of international trade of cannabis. Attorneys from Harris Bricken will provide an overview of the legal landscape on cannabis, and update which countries are the latest to legalize some form of cannabis. We’ll discuss developments in U.S. federal legalization of hemp, hemp-derived products, and marijuana.

If (or when) marijuana is legally allowed to be traded across international borders, we’ll discuss how international trade issues will likely affect the development of the cannabis industry. Trade agreements like the U.S.-Mexico-Canada Agreement (USMCA) could be used to create a North American cannabis industry. However, trade laws are often used to protect domestic industries from import competition. Trade wars could break out to block cannabis imports, particularly where the cannabis industries in different countries are at different stages of development.

We’ll discuss current U.S. regulatory issues affecting the import and export of cannabis, hemp, and CBD products. Our panelists will discuss a range of practical and legal issues related to the importation of cannabis products. A recent ruling from the U.S. Court of International Trade may open the door for the importation of certain products that had previously been prohibited as drug paraphernalia – but the issue remains unsettled meaning importers must continue to proceed with utmost caution.  Finally, we’ll discuss the various intellectual property issues affecting cross-border shipments of cannabis-related products.


Register here!

In the meantime, for more on cannabis and international trade by Adams, Fred, Vince and others here at the Canna Law Blog, check out the following:

Source link

Continue Reading


Copyright © 2021 The Art of MaryJane Media